Tibotec initiates hepatitis C drug global Phase 3 clinical trials
The first global, phase 3, double-blind, randomized study, known as TMC435-C208 or QUEST-1 (QD dosing of TMC435 of previously untreated Genotype 1 patienTs-1), will evaluate a single TMC435
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.